Day: September 17, 2021

A high quality portfolio consisting of 15 dividend yielding Canadian Companies TORONTO, Sept. 17, 2021 (GLOBE NEWSWIRE) — Dividend 15 Split Corp. (the “Company”) is pleased to announce it has completed the overnight offering of Preferred Shares and Class A Shares of the Company. Total gross proceeds of the offering were $100.1 million, bringing the Company’s net assets to approximately $1.5 billion. The shares will begin trading on the Toronto Stock Exchange under the existing symbols of DFN.PR.A (Preferred Shares) and DFN (Class A Shares). The Preferred Shares were offered at a price of $10.05 per Preferred Share to yield 5.5% and the Class A Shares were offered at a price of $8.15 per Class A Share to yield 14.7%. The offering was led by National Bank Financial Inc. The net proceeds of the offering will be used by the Company...

– Conference Dates: September 20th-23rd – BETHESDA, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Wednesday, September 22ndTime:  1:15 to 1:55 p.m. ETPresenter:  Eric Richman, Chief Executive OfficerWebcast:  Registration Link – Click...

TORONTO, Sept. 17, 2021 (GLOBE NEWSWIRE) — MBN Corporation announced that it has filed a notice with the Toronto Stock Exchange (the “TSX”) and received its approval to make a normal course issuer bid (“NCIB”) for its equity shares through the facilities of the TSX. This NCIB will commence on September 23, 2021 and will terminate on September 22, 2022. The Fund had 4,068,098 equity shares issued and outstanding as at September 9, 2021. The Fund may, during the 12 month period commencing September 23, 2021 purchase on the TSX up to 294,975 equity shares, being 10% of the public float and may not, in any 30 day period, purchase more than 81,361 equity shares, being 2% of the equity shares issued and outstanding. The Fund will cancel all equity shares purchased pursuant to the bid. As at September 9, 2021 the Fund had purchased 272,100...

MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced it will be added as a member of the Russell 2000® and 3000® Indexes, effective after the U.S. market opens on September 20, as part of the Russell’s quarterly additions of select initial public offering (“IPO”) companies. “We are honored to be added to the Russell 2000® and 3000® Indexes just a few short months after our IPO, which reflects all of the progress we have made during 2021 to accelerate the commercial adoption of Barostim™, particularly in the U.S.,” said Nadim Yared, President and Chief Executive Officer of CVRx. “We look...

VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) — Major Precious Metals Corp. (“Major Precious Metals” or the “Company”) (CSE:SIZE | OTC:SIZYF | FRANKFURT:3EZ) is pleased to announce that it has successfully completed its Phase 1 diamond drilling program at its Skaergaard Project (“Skaergaard”) in Greenland with all planned drill hole depths covering an area of approximately 10 km² within the 7.5 km (east-west) by 11 km (north-south) Skaergaard intrusion, including key new target zones in the northern part of the Project. HighlightsA total of 32 diamond drill holes (8,195 m) were completed in several key target areas in the northern part of Skaergaard. These target areas were discussed in the Company’s August 26, 2021 news release. Approximately 240 m of channel samples were also collected from four separate areas...

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021. In particular, the results of the interim analysis showed monalizumab in combination with durvalumab improved progression-free survival (PFS) and objective response rate (ORR) compared to durvalumab alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT). Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor...

Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021. In particular, the results of the interim analysis showed monalizumab in combination with durvalumab improved progression-free survival (PFS) and objective response rate (ORR) compared to durvalumab alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT). Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor...